Maggie is an editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.
She has a BA in English from Penn State University. You can connect with Maggie on LinkedIn.
Getting to Know Dr Fabiola Molina, Hospitalist
Fabiola Molina, MD, MHS, is a practicing hospitalist and assistant professor of medicine at Yale School of Medicine and Yale New Haven Hospital. An immigrant from Mexico, her experiences straddling 2 worlds, while attempting to navigate with her family the complicated safety-net system for health care in Texas, were key influences to her ardent focus on health equity.
Part 4: Dr James Robinson on the Impact of 340B Programs and Drug Pricing Policies
In this final part of our interview with James Robinson, PhD, MPH, he underscores the need for employer education about the health plans they offer, fostering managed competition among hospital systems to drive down costs, and innovation in financing drug development.
Part 3: Dr James Robinson on the Impact of 340B Programs and Drug Pricing Policies
In part 3 of our interview with James Robinson, PhD, MPH, he discusses the need for reforms to commercial insurance that reflect the changes to Medicare under the Inflation Reduction Act, how the 340B drug pricing program has veered widely from its original goals, and ongoing cost sharing struggles among patients, insurers, hospitals, and drug companies.
Getting to Know Dr Shauna Downs, Public Health Nutritionist
Shauna Downs, PhD, MS, is an associate professor in the Department of Health Behavior, Society, and Policy at the Rutgers School of Public Health. A former figure skater, her research now focuses on interventions to promote healthy and sustainable food choices and exploring how our changing climate, food systems, diet, and nutrition are inextricably linked.
Part 2: Dr James Robinson on the Impact of 340B Programs and Drug Pricing Policies
In part 2 of our interview with Robinson, he addresses the potential for exacerbated health care disparities in the aftermath of hospital price markups and how insurance plan design often disadvantages the patients who most need expensive infusion therapies but cannot afford them.
Getting to Know Dr Doug Marks, Oncology Clinical Trialist
Douglas K. Marks, MD, is a breast medical oncologist and director of the Clinical Trials Office, Perlmutter Cancer Center, NYU Langone Hospital—Long Island, as well as associate professor in the Department of Medicine at NYU Grossman Long Island School of Medicine. As a phase 1 clinical trialist, he sees both patients with breast cancer and those who are looking to receive innovative treatments for their early-stage disease.
Part 1: Dr James Robinson on the Impact of 340B Programs and Drug Pricing Policies
In the January issue of The New England Journal of Medicine, James Robinson, PhD, MPH, and his fellow investigators published their findings from an analysis of how insurer drug expenditures on infused drugs influenced price markups at hospitals.
Daratumumab-Based Regimen Potential Promising Bridging Therapy for RRMM
The combination of daratumumab and immumodulatory therapy was evaluated among patients with relapsed/refractory multiple myeloma (RRMM) who have failed prior treatment with immunomodulatory agents, proteasome inhibitors, and daratumumab as monotherapy or in combination.
In Adolescents With Obesity, FMT Shows No Negative Impact on Horizontal Gene Transfer
For this analysis, investigators used metagenomic sequencing files from the Gut Bugs trial, a placebo-controlled multidonor fecal microbiota transplantation (FMT) trial conducted among adolescents classified as obese.
Durvalumab Consolidation Therapy Shows Promise in Elderly Patients With Stage III NSCLC
Consolidation durvalumab led to comparable outcomes among older patients with unresectable stage III non–small cell lung cancer (NSCLC) vs a younger cohort with the same cancer; this patient population was underrepresented in the PACIFIC trial.
Dr Chandler Cortina: In Oncology, We Treat the Disease and the Person
In this interview, Chandler Cortina, MD, MS, FSSO, FACS, Froedtert & the Medical College of Wisconsin, addresses the impact that prioritizing mental health care can have on patients as they navigate through their cancer journey.
Getting to Know Dr Chandler Cortina, Breast Surgical Oncologist
Chandler Cortina, MD, MS, FSSO, FACS, is assistant professor of surgery and breast surgical oncologist at Froedtert & the Medical College of Wisconsin. His current research focuses on breast cancer risk not only in general but also among transgender and gender-diverse populations.
COA's Dr Miriam Atkins: PBMs, HR 5526, and Marketplace Strategy
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance, discusses the impact of pharmacy benefit managers (PBMs) on health care costs and offers potential ways to remedy certain CMS decisions that negatively affect oncologists and their patients.
Pre-, Postinfusion Protocol Recommendations for Delandistrogene Moxeparvovec Use in DMD
The gene therapy delandistrogene moxeparvovec-rokl, also known as Elevidys (Sarepta Therapeutics) is indicated to treat Duchenne muscular dystrophy (DMD) in ambulatory patients aged 4 to 5 years, and Sarepta recently filed supplemental data with the FDA seeking to expand the labeled indication.
Translating DMD Clinical Trial Findings to Real-World Application Discouraging
This analysis compared outcomes among patients who have Duchenne muscular dystrophy (DMD) and commercial insurance or Medicaid, focusing on how these differ between patients in clinical trials and those who receive treatment post approval.
Navigating Single Motherhood, Mental Health, and Finding Support Amidst Challenges
UPMC Health Plan member Marjorie Robinson, of Monroeville, Pennsylvania, tells of her experiences with Pittsburgh-based Fabric Health as a single mom of 2 teenagers and why she believes that mental health–related concerns can be significant obstacles to overall good health.
Best Practices That Target Selinexor Treatment Improve MM-Related Outcomes
Patient survival and such treatment-related outcomes as time to treatment failure and treatment duration improved following implementation of a best practices program that focused on selinexor administration for multiple myeloma (MM), with implications for other anticancer medications.
Housing Stability and Adequate Health Care Are Crucial for Mental and Physical Health
Serena Sloane, a Pittsburgh-based certified nursing assistant, took advantage of a chance meeting at her laundromat with someone from Fabric Health to learn more about her options for bettering her health care benefits
DMD Guidance Could Benefit From Update, Experts Say
MEDLINE, the Turning Research Into Practice database, Google Scholar, and organization guidelines were searched for their ongoing applicability to the management of Duchenne muscular dystrophy (DMD) and to determine if there is a need to develop new treatment recommendations.
Sacituzumab Govitecan Monotherapy for NSCLC Disappoints in EVOKE-01 Trial Update
The TROP-2–directed antibody drug conjugate is currently being investigated as a monotherapy and a combination therapy for non–small cell lung cancer (NSCLC) in 3 trials: phase 3 EVOKE-01, phase 2 EVOKE-02, and phase 3 EVOKE-03.
Analysis Explores Gene Therapy’s Potential to Be Cost-Effective in SCD
This new economic valuation of the societal and health care benefits of gene therapy to treat sickle cell disease (SCD) concludes the highly personalized treatment has potential to be cost effective if priced below $2 million.